Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 6 | 2022 | 163 | 1.820 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2012 | 243 | 1.040 |
Why?
|
| Carcinogenesis | 2 | 2022 | 22 | 0.950 |
Why?
|
| Adenoma | 2 | 2022 | 61 | 0.900 |
Why?
|
| Lung Neoplasms | 6 | 2012 | 555 | 0.870 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 84 | 0.850 |
Why?
|
| Glioblastoma | 1 | 2021 | 9 | 0.760 |
Why?
|
| DNA Damage | 1 | 2021 | 27 | 0.760 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 60 | 0.750 |
Why?
|
| MicroRNAs | 1 | 2022 | 51 | 0.750 |
Why?
|
| Carcinoma | 1 | 2022 | 68 | 0.740 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 89 | 0.710 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2021 | 11 | 0.710 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2021 | 29 | 0.680 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 141 | 0.510 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 105 | 0.480 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 113 | 0.440 |
Why?
|
| Genes, p16 | 1 | 2012 | 4 | 0.410 |
Why?
|
| Quinazolines | 3 | 2012 | 16 | 0.400 |
Why?
|
| Germ-Line Mutation | 3 | 2021 | 14 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 175 | 0.360 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2020 | 36 | 0.350 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 7 | 0.340 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 11 | 0.340 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 14 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2007 | 50 | 0.340 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 33 | 0.340 |
Why?
|
| Aged | 15 | 2021 | 9098 | 0.320 |
Why?
|
| Long Interspersed Nucleotide Elements | 2 | 2021 | 5 | 0.320 |
Why?
|
| Endometrial Neoplasms | 2 | 2021 | 13 | 0.320 |
Why?
|
| Female | 17 | 2021 | 15336 | 0.310 |
Why?
|
| Humans | 22 | 2022 | 27371 | 0.300 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 72 | 0.300 |
Why?
|
| Middle Aged | 12 | 2021 | 9057 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 5 | 0.280 |
Why?
|
| Adult | 9 | 2021 | 7905 | 0.270 |
Why?
|
| Age Factors | 2 | 2021 | 771 | 0.240 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 208 | 0.240 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 410 | 0.240 |
Why?
|
| Genetic Testing | 2 | 2016 | 57 | 0.230 |
Why?
|
| Male | 12 | 2021 | 14909 | 0.230 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 56 | 0.220 |
Why?
|
| DNA Repair Enzymes | 2 | 2016 | 7 | 0.220 |
Why?
|
| GTP Phosphohydrolases | 2 | 2020 | 6 | 0.210 |
Why?
|
| Genes, BRCA1 | 2 | 2020 | 12 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 21 | 0.210 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 65 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2020 | 165 | 0.190 |
Why?
|
| Genes, p53 | 2 | 2020 | 18 | 0.190 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2021 | 4 | 0.190 |
Why?
|
| Prognosis | 3 | 2018 | 805 | 0.180 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 7 | 0.180 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2020 | 5 | 0.180 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 10 | 0.180 |
Why?
|
| Intestinal Mucosa | 1 | 2022 | 159 | 0.180 |
Why?
|
| Survival Rate | 2 | 2012 | 349 | 0.170 |
Why?
|
| Phthalazines | 1 | 2020 | 6 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 5 | 0.170 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 369 | 0.170 |
Why?
|
| Piperazines | 1 | 2020 | 78 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 206 | 0.160 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2018 | 8 | 0.160 |
Why?
|
| DNA-Binding Proteins | 2 | 2021 | 274 | 0.150 |
Why?
|
| Thyroid Gland | 1 | 2018 | 42 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 44 | 0.150 |
Why?
|
| Hematopoiesis | 1 | 2018 | 12 | 0.150 |
Why?
|
| Chimerism | 1 | 2018 | 4 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 4 | 0.150 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 3 | 0.150 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 4 | 0.150 |
Why?
|
| Chromosomes, Human | 1 | 2018 | 6 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 194 | 0.150 |
Why?
|
| Genetic Markers | 1 | 2018 | 47 | 0.150 |
Why?
|
| X-linked Nuclear Protein | 1 | 2017 | 2 | 0.140 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2017 | 3 | 0.140 |
Why?
|
| Adenomatous Polyps | 1 | 2017 | 4 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 42 | 0.130 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2016 | 5 | 0.130 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2016 | 3 | 0.130 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 8 | 0.130 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 11 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 113 | 0.130 |
Why?
|
| Mutation | 5 | 2018 | 347 | 0.130 |
Why?
|
| ErbB Receptors | 4 | 2012 | 53 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 88 | 0.130 |
Why?
|
| Young Adult | 1 | 2021 | 2020 | 0.120 |
Why?
|
| CpG Islands | 2 | 2017 | 54 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 179 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 4796 | 0.110 |
Why?
|
| Cervix Mucus | 1 | 2013 | 4 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2018 | 587 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 25 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 93 | 0.100 |
Why?
|
| Genital Neoplasms, Female | 1 | 2013 | 14 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 28 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 366 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 83 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2012 | 3553 | 0.100 |
Why?
|
| Brain | 1 | 2021 | 1648 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 19 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2012 | 77 | 0.100 |
Why?
|
| Illinois | 1 | 2012 | 249 | 0.100 |
Why?
|
| Meiosis | 1 | 2010 | 1 | 0.090 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2010 | 12 | 0.090 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 11 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2010 | 21 | 0.090 |
Why?
|
| Disease Progression | 2 | 2018 | 682 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2010 | 38 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 106 | 0.090 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2010 | 4 | 0.090 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 4 | 0.090 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2010 | 5 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 31 | 0.090 |
Why?
|
| Cadherins | 1 | 2010 | 32 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 53 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 57 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1811 | 0.080 |
Why?
|
| Lung | 1 | 2010 | 168 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 45 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 28 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 22 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2007 | 3 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 121 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2007 | 261 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 114 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 245 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 350 | 0.060 |
Why?
|
| Logistic Models | 1 | 2007 | 399 | 0.060 |
Why?
|
| Patient Selection | 1 | 2007 | 198 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 425 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2020 | 3590 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 383 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2021 | 20 | 0.050 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 6 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 85 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2020 | 10 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2021 | 75 | 0.040 |
Why?
|
| Standard of Care | 1 | 2020 | 14 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 350 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 484 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 10 | 0.040 |
Why?
|
| Galectin 3 | 1 | 2018 | 4 | 0.040 |
Why?
|
| Galectins | 1 | 2018 | 6 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 24 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2018 | 25 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2018 | 19 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 140 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2018 | 222 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 492 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 58 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 1451 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 647 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 52 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2012 | 19 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 313 | 0.020 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2010 | 2 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 60 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 127 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 442 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 4 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 6 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 11 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2008 | 49 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 42 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 175 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 14 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2008 | 59 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 220 | 0.020 |
Why?
|